KIAA1549

Chr 7AR

KIAA1549

Also known as: RP86

The protein encoded by this gene belongs to the UPF0606 family. This gene has been found to be fused to the BRAF oncogene in many cases of pilocytic astrocytoma. The fusion results from 2Mb tandem duplications at 7q34. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2012]

Primary Disease Associations & Inheritance

Retinitis pigmentosa 86MIM #618613
AR
577
ClinVar variants
9
Pathogenic / LP
0.99
pLI score· haploinsufficient
8
Active trials
Clinical SummaryKIAA1549
🧬
Gene-Disease Validity (ClinGen)
retinitis pigmentosa 86 · ARStrong

Strong evidence — appropriate for clinical testing

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 0.99). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
9 Pathogenic / Likely Pathogenic· 345 VUS of 577 total submissions
💊
Clinical Trials
8 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
0.29LOEUF
pLI 0.986
Z-score 6.15
OE 0.18 (0.120.29)
Highly constrained

Highly LoF-intolerant (top ~10% of genes)

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-0.09Z-score
OE missense 1.01 (0.961.06)
1121 obs / 1112.3 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.18 (0.120.29)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.01 (0.961.06)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.07
01.21.6
LoF obs/exp: 12 / 65.9Missense obs/exp: 1121 / 1112.3Syn Z: -1.23

ClinVar Variant Classifications

577 submitted variants in ClinVar

Classification Summary

Pathogenic6
Likely Pathogenic3
VUS345
Likely Benign214
Conflicting9
6
Pathogenic
3
Likely Pathogenic
345
VUS
214
Likely Benign
9
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
1
0
5
0
6
Likely Pathogenic
2
0
1
0
3
VUS
5
321
10
9
345
Likely Benign
0
10
42
162
214
Benign
0
0
0
0
0
Conflicting
9
Total833158171577

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

KIAA1549 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

KIAA1549-related retinitis pigmentosa

limited
ARUndeterminedAltered Gene Product Structure
Eye
G2P ↗
missense variantinframe deletioninframe insertion

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

KIAA1549 GENE; KIAA1549
MIM #613344 · *

Retinitis pigmentosa 86

MIM #618613

Molecular basis of disorder known

Autosomal recessive
📖
GeneReview available — KIAA1549
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence
Key Publications
Landmark & review papers · by relevance
PubMed
[Pediatric Glioma].
Terashima K et al.·No Shinkei Geka
2021
BRAF alterations in primary brain tumors.
Maraka S et al.·Discov Med
2018Review
Top 10 resultsSearch PubMed ↗

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Low-grade GliomaPediatric Low-grade GliomaspLGG With BRAF Alteration

FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration

NOT YET RECRUITING
NCT07004075Phase PHASE3Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.Started 2025-06-30
LuvometinibChemotherapeutic Agent COG-V/C Carboplatin + Vindesine, Carboplatin, Temozolomide
High Grade Glioma (HGG) of the Brain With BRAF AberrationHigh Grade Glioma (III or IV)Diffuse Intrinsic Pontine Glioma

Study of Tovorafenib in High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)

NOT YET RECRUITING
NCT07206849Phase PHASE2Nationwide Children's HospitalStarted 2026-03-01
Tovorafenib
Low-grade Glioma

Pilot Study of Vinblastine and Tovorafenib in Pediatric Patients With Recurrent/Progressive RAF Altered Low Grade Gliomas

RECRUITING
NCT06381570Phase EARLY_PHASE1Daniel MorgensternStarted 2024-03-21
TovorafenibVinblastine
Pediatric Low-grade Glioma

Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

RECRUITING
NCT06666348Phase PHASE1, PHASE2St. Justine's HospitalStarted 2026-01-12
Mirdametinib
Low Grade GliomaRecurrent Childhood Pilocytic AstrocytomaRecurrent Neurofibromatosis Type 1

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

ACTIVE NOT RECRUITING
NCT01089101Phase PHASE1, PHASE2National Cancer Institute (NCI)Started 2010-07-07
Biospecimen CollectionSelumetinib
Low Grade GliomaHigh Grade Glioma

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

RECRUITING
NCT06712875Phase PHASE1, PHASE2Ann & Robert H Lurie Children's Hospital of ChicagoStarted 2025-04-01
Trametinib and NivolumabDabrafenib, trametinib, nivolumab
Low Grade Glioma

Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)

ACTIVE NOT RECRUITING
NCT02840409Phase PHASE2The Hospital for Sick ChildrenStarted 2016-08-01
VinblastineBevacizumab
Low-grade GliomaPlexiform NeurofibromaCentral Nervous System Glioma

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

ACTIVE NOT RECRUITING
NCT03363217Phase PHASE2St. Justine's HospitalStarted 2018-08-16
Trametinib